Markets:

Overview

News

Currencies

International

Treasuries

MBX Biosciences, Inc. - Common Stock (NQ:MBX)

29.15 -0.65 (-2.18%)

Streaming Delayed Price Updated: 10:52 AM EDT, Mar 17, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about MBX Biosciences, Inc. - Common Stock

< Previous 1 2 Next >

Amylyx Eyes $2B Opportunity In Post-Surgery Sugar Crash Market ↗

June 24, 2025

Guggenheim initiates Amylyx at Buy with $17 price forecast, citing PBH drug avexitide's Phase 3 potential and $2 billion+ market opportunity.

Via Benzinga

Earnings Scheduled For February 13, 2025 ↗

February 13, 2025

Via Benzinga

These 5 Health Care Stocks Saw The Sharpest Retail Interest Jump Last Week ↗

February 10, 2025

These five small-cap pharma and biotech stocks drew heavy attention on Stocktwits last week, driven by key trial results, FDA updates, and promising drug developments.

Via Stocktwits

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

February 06, 2025

Via Benzinga

Why Logility Supply Chain Solutions Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket ↗

January 27, 2025

Via Benzinga

Topics Economy

Applied Digital, Vericel, Calavo Growers And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

January 15, 2025

Via Benzinga

Why Vision Marine Technologies Shares Are Trading Higher By 68%; Here Are 20 Stocks Moving Premarket ↗

January 15, 2025

Via Benzinga

How Richard DiMarchi Revolutionized Diabetes Treatment ↗

January 09, 2025

Antiobesity drugs are amazing people by how fast they melt off pounds. But it's no surprise to Richard DiMarchi.

Via Investor's Business Daily

MBX Biosciences' Investigational Drug For Weight Loss Surgery-Related Low Blood Sugar Shows Encouraging Action ↗

January 07, 2025

MBX Biosciences reports Phase 1 trial results for MBX 1416, a GLP-1 receptor antagonist for post-bariatric hypoglycemia. Phase 2 starts in 2025.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

January 02, 2025

Via Benzinga

Earnings Scheduled For December 19, 2024 ↗

December 19, 2024

Via Benzinga

StandardAero Surges In Market Debut ↗

October 06, 2024

Shares of StandardAero jumped 36% in the company's trading debut as the aircraft maintenance services provider raised $1.44 billion in its IPO. Additionally, Chain Bridge Bancorp opened on Oct. 5 at...

Via Talk Markets

Topics Initial Public Offering

Trio Of Biotech IPOs Climb In Debut ↗

September 15, 2024

A trio of biotech companies' shares rose on Friday in their first trading sessions. Bicara Therapeutics, MBX Biosciences, and Zenas BioPharma each sold more shares in their respective initial public...

Via Talk Markets

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.